AIkido Pharma Inc., USA  has announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., USA, which focuses on the non-nuclear supply of enriched isotopes.

ASP Isotopes' uses Aerodynamic Separation Process for enriching molybdenum-100, which is a stable isotope of molybdenum, currently of great interest for production of Technetium-99m. Technetium-99m is the most used radioisotope in the nuclear imaging industry, but the supply chain, which involves the radioactive decay of molybdenum-99 has been fraught with problems during the last 10-12 years. Mo-100 can be converted into Technetium-99m at an accelerator, closer to the point of care thus eliminating the complex supply chain that currently exists. It also removes the risk of a supply interruption to the hospital and radiological pharmacy. ASP Isotopes is currently constructing a 20 Kg/year production plant in South Africa (during 2021/22).

Paul Mann, Chairman and CEO of ASP Isotopes commented: "The ASP Technology has been developed over the last 18 years. Following this capital raise, we believe that we are in a strong position to complete our first manufacturing plant for Molybdenun-100. We would like to thank AIkido Pharma for their strategic investment in ASP Isotopes and we look forward to delivering extraordinary shareholder returns over the next several years".

To read more please visit:

AIkido Pharma Announces Strategic Interest in ASP Isotopes Inc

Source: CISION